Epilepsy with myoclonic atonic seizures
ICD-10 G40.4 · ICD-11 8A61.2Y.2

Treatment of Epilepsy with Myoclonic Atonic Seizures in a Pathogenic SLC6A1 Gene Variant

When epilepsy with myoclonic atonic seizures is associated with a confirmed pathogenic variant in the SLC6A1 gene, the underlying genetic aetiology is a central consideration in selecting the appropriate management strategy.

Clinical scenario: Myoclonic atonic seizures in a patient carrying a pathogenic variant in the SLC6A1 gene. Valproate has been reported as the most effective agent in SLC6A1-related epilepsies, with lamotrigine and ethosuximide also showing efficacy in this population.
Treatment approach

The protocol for this SLC6A1-variant context includes a targeted pharmacological agent that has been evaluated specifically in children carrying pathogenic SLC6A1 variants. The complete selection criteria, agent, and management sequence are detailed in the full protocol.

Dosing details, sequencing, and full regimen are available behind the link below.

Treatment goal

Primary target: improved seizure control.

Instant Access to Structured Evidence-Based Regimens

References

  • Valproate has been reported as the most effective drug for SLC6A1-related epilepsies, with lamotrigine and ethosuximide also showing efficacy.
  • Based on evidence from a preprint paper, treatment of children with pathogenic STXBP1 or SLC6A1 variants with 4-phenylbutyrate resulted in improved seizure control in a single-treatment, multiple-dose, open-label study.
View source ↗